In the published article, there was an error in the legend for Figure 2 as published. In the legend for Figure 2, “(N) Brown adipose tissue (BAT).” is a duplicate and needs to be deleted because the BAT is explained in the legend for Figure 2I. The corrected legend appears below.
“FIGURE 2 | EPC ameliorated MAFLD in rats. (A) Body weight (BW). (B) BW gain. (C–E) Organ wet weight. (F) Inguinal white adipose tissue (iWAT). (G) Perirenal white adipose tissue (pWAT). (H) Epididymis white adipose tissue (eWAT). (I) Brown adipose tissue (BAT). (J) iWAT/BW ratio. (K) pWAT/BW ratio; (L) eWAT/BW rati. (M) BAT/BW ratio. (N) Representative rat liver images of hematoxylin and eosin (H and E) and Oil Red O staining per group (X200). (O) Representative iWAT, pWAT, eWAT, BAT. One-way analysis of variance (ANOVA) was conducted for the group comparison. n = 8, data are presented as mean ± SEM.*p < 0.05, **p < 0.01, ***p < 0.001 vs. MOD group. EPC, P. cocos ethanol extract; CON, normal diet control group; MOD, high-fat diet group; FC, Fenofibrate capsules; EPC-L, low-dose P. cocos ethanol extract; EPC-H, high-dose P. cocos ethanol extract.].
Furthermore, there was an error in Figure 6P as published. The authors apologize for uploading the ERK protein image in Figure 6 incorrectly, with image of p-JNK, in this article. Furthermore, P-ERK should be p-ERK in Figure 6P. The corrected Figure 6 appears below.
FIGURE 6
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
MAFLD (metabolic-associated fatty liver disease), Poria cocos (Schw.) Wolf., bile acid metabolism, FXR/PPARα-SREBP pathway, lipid homeostasis, UPLC Q-TOF/MS
Citation
He J, Yang Y, Zhang F, Li Y, Li X, Pu X, He X, Zhang M, Yang X, Yu Q, Qi Y, Li X and Yu J (2023) Corrigendum: Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway. Front. Pharmacol. 14:1172950. doi: 10.3389/fphar.2023.1172950
Received
24 February 2023
Accepted
15 May 2023
Published
19 May 2023
Volume
14 - 2023
Edited and reviewed by
Michael Heinrich, University College London, United Kingdom
Updates
Copyright
© 2023 He, Yang, Zhang, Li, Li, Pu, He, Zhang, Yang, Yu, Qi, Li and Yu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yan Qi, qiyankm@ynutcm.edu.cn; Xuefang Li, lixuef100@126.com; Jie Yu, cz.yujie@gmail.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.